---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-025392"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2022-07-06T23:59:59+00:00"
generated_at: "2026-06-24T20:59:33.469933+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AbCellera loses Chief Business Officer Neil Berkley effective June 29, 2022

## Summary
- Neil Berkley departed as Chief Business Officer effective June 29, 2022; not due to any disagreement with the Company.
- Berkley qualifies for severance benefits under the Company's Executive Severance Plan (terms previously disclosed in proxy statement).
- No successor named in the filing; departure is effective immediately.

## SEC filing metadata
- accession: 0001564590-22-025392
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2022-07-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000156459022025392/0001564590-22-025392-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000156459022025392/abcl-8k_20220629.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-025392
- JSON: https://secwatch.observer/filing/0001564590-22-025392.json
- Plain text: https://secwatch.observer/filing/0001564590-22-025392.txt

## Key facts
- Executive change
  Neil Berkley departed as Chief Business Officer at AbCellera Biologics Inc..
  - Action: departed
  - Role: Chief Business Officer
  source text: Effective June 29, 2022, Neil Berkley is no longer the Chief Business Officer of AbCellera Biologics Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703057/000156459022025392/0001564590-22-025392-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.